Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells.
- Author:
Ji Sung KIM
1
;
Yong Guk KIM
;
Minji PYO
;
Hong Kyung LEE
;
Jin Tae HONG
;
Youngsoo KIM
;
Sang Bae HAN
Author Information
- Publication Type:In Vitro ; Review
- Keywords: Melanoma; Preclinical study; Cytokine-induced killer cells
- MeSH: Cell- and Tissue-Based Therapy*; Cytokine-Induced Killer Cells*; Drug Resistance; Heterografts; Humans; Incidence; Lymphocytes, Tumor-Infiltrating; Melanoma*; Prognosis; Protein-Tyrosine Kinases; Skin Neoplasms; Survival Rate
- From:Immune Network 2015;15(2):58-65
- CountryRepublic of Korea
- Language:English
- Abstract: Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity.
